Risacare Injection

Adult administration

The recommended therapeutic regimen for this medication is to administer the entire bag of injection solution together with Lutetium-177 (177Lu) oxodotreotide. For optimal kidney protection, it should be administered by intravenous infusion over 4 hours (250 mL/hr) starting 30 minutes prior to the administration of Lutetium (177Lu) oxodotreotide. This drug and Lutetium (177Lu) oxodotreotide should be administered separately into different veins. Intravenous administration

This medication should not be used in patients who have had an allergic reaction to this drug or any of its components. Additionally, it should not be administered to patients with elevated serum potassium levels or severely reduced kidney function before administration. Caution is required when using this medication in patients with high serum potassium levels, severe heart failure, metabolic acidosis, or impaired kidney or liver function, and relevant tests should be conducted prior to administration. This medication mainly contains amino acids arginine and lysine; during administration, serum potassium levels may temporarily increase, so monitoring is necessary. In cases of hyperkalemia, symptoms may appear, so it is essential to closely observe for signs such as difficulty breathing, weakness, chest pain, and heart abnormalities. Sufficient fluid intake is recommended during the administration of this drug, and frequent urination is encouraged. In patients with severe heart failure, care must be taken with the volume and osmotic pressure of this medication due to the risk of complications. Attention should also be paid when administering to patients with metabolic acidosis, and most symptoms resolve within 24 hours post-administration. The safety of this drug has not been fully established in pregnant women or nursing mothers; consultation with a specialist is advised if necessary. The safety and efficacy of this drug have not been adequately studied in children or elderly patients, hence caution is needed when using. In patients with impaired kidney or liver function, functional tests should be conducted prior to administration, and the benefits and risks of treatment should be carefully considered if necessary. In cases of overdose, excessive fluid or solute may occur; forced diuresis or frequent urination should be used to promote excretion. This drug should not be mixed or diluted with other medications, and it should be stored at or below 25 degrees Celsius, being a single-use item that must be used immediately after opening. Do not use if the packaging is damaged, discolored, or if there are precipitates.

Serious side effects

Cardiovascular symptoms due to hyperkalemia (conduction abnormalities, cardiac arrhythmias), and signs and symptoms of hyperkalemia (difficulty breathing, weakness, numbness, chest pain, etc.)

Mild side effects

• Nausea
• vomiting
• hyperkalemia
• dizziness
• headache
• flushing
• abdominal pain

This medication should be stored in a sealed container to prevent exposure to air or moisture. Additionally, it is important to store it in a cool place at a temperature between 1 to 25 degrees Celsius to maintain its efficacy.

Appearance

An injection solution that is a colorless and transparent liquid contained in a colorless and transparent bag for infusions.

Package unit

1000 milliliters/bag